THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.

Twitter Linkedin Search

COVend presented at ISPOR Europe 2023

On the 13th of November, the consortium member of our partner institution UMCG, Clazinus Veijer, presented his poster “Lessons learned from model-based economic evaluations of COVID-19 treatments under pandemic circumstances: results from a systematic review ” at ISPOR Europe 2023. The poster highlighted results from a systematic review of various methodological characteristics of model-based economic evaluations of COVID-19 treatments.
 
Together with the rest of the UMCG team, Clazinus works on socio-economic impact and cost-effectiveness analyses of FX06 under WP7 in the COVend project. The study conducted by Clazinus Veijer, Thea van Asselt, Marinus (René) van Hulst, Maarten Postma and Benjamin Friedrichson aimed to analyse key methodological choices made in model-based economic evaluations of COVID-19 treatments, and specifically focused on model choices which pertain to disease dynamics, model structure, and long-term sequelae. conducted a systematic literature review and searched key databases (including MEDLINE, EMBASE, Web of Science, Scopus) for original articles on model-based full economic evaluations of COVID-19 drug treatments. The research team found that disease dynamics of COVID-19 patients in the acute phase were incorporated in 25 studies (92.6%). Hypothetical cohorts were mainly stratified by respiratory support and level of care management. A Markov model was applied in 59.3% of studies, whether or not preceded by a decision tree or an epidemiological model. Number of health states used in Markov models ranged from 2 up to 17 health states. Of 10 studies with a lifetime horizon, 7 made adjustments to general population estimates to account for long-term sequelae, lasting for one year, five years or a patient’s lifetime for patients discharged after mechanical ventilation or with moderate or severe health issues. These results illustrate the differences in modelling COVID-19 treatments and could serve as a starting point in the discussion on an adequate response from a health-economic perspective towards future healthcare-related emergencies.

The poster was one of many other interesting posters and it was a great opportunity to share and discuss results of the systematic review on several methodological characteristics of model-based economic evaluations of COVID-19 treatments. Overall, the conference opened up many ways to get to know others working in the same field and offered a wide range of knowledge sessions related to HEOR.

Clazinus Veijer

ISPOR is the leading global scientific and educational organization for health economics and outcomes research and their use in decision-making to improve health. The Society’s mission is to promote health economics and outcomes research excellence to improve decision-making for health globally.
 
Aknowledgement to the valuable contribution of the co-authors: Thea van Asselt, Marinus (René) van Hulst, Maarten Postma, Benjamin Friedrichson
 
The poster is available for download on our webpage page “Media Corner”.
 

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

FOR INQUIRIES, PLEASE SEND US AN EMAIL AT [email protected]

Twitter Linkedin

© accelopment Schweiz AG  · [email protected] · ISO 9001 certified · Read our Privacy Policy